136777-48-5 | Abacavir sulfate

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$63.00	$45.00
10mg	98%	in stock	$94.00	$66.00
50mg	98%	in stock	$251.00	$176.00
100mg	98%	in stock	$371.00	$260.00
250mg	98%	in stock	$530.00	$371.00
1g	98%	in stock	$1,071.00	$750.00

Description

• Catalog Number: AE34788
• Chemical Name: Abacavir sulfate
• CAS Number: 136777-48-5
• Molecular Formula: C14H19ClN6O
• Molecular Weight: 322.7933
• MDL Number: MFCD18427212
• SMILES: OC[C@@H]1C=C[C@@H](C1)n1cnc2c1nc(N)nc2NC1CC1.Cl

Computed Properties

• Complexity: 496
• Covalently-Bonded Unit Count: 3
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 47
• Hydrogen Bond Acceptor Count: 16
• Hydrogen Bond Donor Count: 8
• Rotatable Bond Count: 8

Literature

• T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms.

  Chemical research in toxicology 20130520

• N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

  British journal of pharmacology 20121101

• A case of adverse drug reaction induced by dispensing error.

  Journal of forensic and legal medicine 20121101

• Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

  Journal of pharmacy practice 20121001

• Trade deal to curb generic-drug use.

  Nature 20120906

• Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity.

  Genetic testing and molecular biomarkers 20120901

• Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children.

  British journal of clinical pharmacology 20120801

• Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

  AIDS (London, England) 20120717

• Avidity determines T-cell reactivity in abacavir hypersensitivity.

  European journal of immunology 20120701

• Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

  Nature 20120628

• Pharmacology: A false sense of non-self.

  Nature 20120627

• Detection of abacavir hypersensitivity by ELISpot method.

  Inflammation & allergy drug targets 20120601

• Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp.

  Therapeutic delivery 20120601

• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  Gastroenterology 20120501

• Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

  British journal of clinical pharmacology 20120401

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• HLA alleles and drug hypersensitivity reactions.

  International journal of immunogenetics 20120401

• Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.

  HIV medicine 20120401

• Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

  Clinical pharmacology and therapeutics 20120401

• Enantioselective synthesis of the carbocyclic nucleoside (-)-abacavir.

  Organic & biomolecular chemistry 20120307

• Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.

  AIDS research and human retroviruses 20120301

• Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

  Journal of the American Chemical Society 20120215

• Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

  Clinical pharmacology and therapeutics 20120201

• Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

  Human immunology 20120201

• [Coinfection with HIV and HCV: abacavir and ribavirine, why not?].

  Revista clinica espanola 20120101

• Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.

  Annual review of pharmacology and toxicology 20120101

• Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

  AIDS patient care and STDs 20120101

• Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

  PloS one 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

  Antiviral therapy 20120101

• Genetics and the potential for predictive tests in adverse drug reactions.

  Chemical immunology and allergy 20120101

• Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.

  Journal of the International AIDS Society 20120101

• The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

  Antiviral therapy 20120101

• Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity.

  Chemical research in toxicology 20111219

• Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.

  The Journal of infectious diseases 20111215

• Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

  AIDS (London, England) 20111128

• Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

  AIDS (London, England) 20111023

• Abacavir and myocardial infarctions: the benefit of doubt?

  AIDS (London, England) 20111023

• Optimizing initial therapy for HIV infection.

  The Journal of infectious diseases 20111015

• Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

  The Journal of infectious diseases 20111015

• Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.

  The Journal of infectious diseases 20111015

• A new approach to safely type for HLA the HIV infected people eligible to abacavir therapy: saliva or buccal swab as reliable DNA sources.

  Clinica chimica acta; international journal of clinical chemistry 20111009

• Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20111001

• Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.

  AIDS patient care and STDs 20111001

• [Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].

  Deutsche medizinische Wochenschrift (1946) 20111001

• A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

  The Journal of infectious diseases 20110915

• Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

  British journal of clinical pharmacology 20110901

• Abacavir and lamivudine for the treatment of human immunodeficiency virus.

  Expert opinion on pharmacotherapy 20110901

• [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].

  Medecine et maladies infectieuses 20110901

• Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic.

  Central European journal of public health 20110901

• Medication-based urolithiasis and atazanavir.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110809

• Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

  The Journal of antimicrobial chemotherapy 20110801

• Treatment of Asian flush with abacavir.

  Medical hypotheses 20110801

• Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.

  Clinics (Sao Paulo, Brazil) 20110801

• Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.

  Clinica chimica acta; international journal of clinical chemistry 20110715

• Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701

• HIV and Cardiovascular Disease.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701

• Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

  AIDS (London, England) 20110619

• Acetoxy Meldrum's acid: a versatile acyl anion equivalent in the Pd-catalyzed asymmetric allylic alkylation.

  Organic letters 20110617

• Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.

  The Pediatric infectious disease journal 20110601

• Can fomepizole be substituted by abacavir in the treatment of methanol poisoning?

  Journal of medical toxicology : official journal of the American College of Medical Toxicology 20110601

• Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.

  Pharmacogenomics 20110601

• Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

  AIDS research and human retroviruses 20110501

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.

  Expert opinion on drug safety 20110501

• Hypersensitivity reactions to HIV therapy.

  British journal of clinical pharmacology 20110501

• FDA notifications. Abacavir sulfate tablets tentatively approved.

  AIDS alert 20110501

• FDA notifications. Ongoing safety review of abacavir, possible MI risk.

  AIDS alert 20110501

• No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110401

• Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.

  Pharmacogenomics 20110401

• Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

  AIDS research and human retroviruses 20110201

• Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

  Tropical medicine & international health : TM & IH 20110201

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20110201

• Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20110125

• The toxicogenetics of antiretroviral therapy: the evil inside.

  Current medicinal chemistry 20110101

• Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.

  Journal of biopharmaceutical statistics 20110101

• Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

  BMC infectious diseases 20110101

• Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.

  Internal medicine (Tokyo, Japan) 20110101

• [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].

  Enfermedades infecciosas y microbiologia clinica 20110101

• Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol.

  PloS one 20110101

• Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

  Antiviral therapy 20110101

• Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

  Antiviral therapy 20110101

• Increased prevalence of albuminuria in HIV-infected adults with diabetes.

  PloS one 20110101

• Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection.

  Current problems in diagnostic radiology 20110101

• Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

  BMC infectious diseases 20110101

• Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.

  Antiviral therapy 20110101

• The impact of pharmacogenetics in the treatment of allergic disease and asthma.

  Missouri medicine 20110101

• Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.

  Antiviral therapy 20110101

• Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.

  Dermatologic therapy 20110101

• [HLA-B*5701 and abacavir hypersensitivity reaction].

  Pathologie-biologie 20101201

• HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.

  Georgian medical news 20101201

• Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.

  AIDS (London, England) 20101113

• Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.

  Enfermedades infecciosas y microbiologia clinica 20101101

• Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

  The Journal of antimicrobial chemotherapy 20101101

• FDA notifications. FDA approves generic abacavir.

  AIDS alert 20101101

• Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101001

• The impact of gender and anchor drugs on TDF renal toxicity.

  Journal of acquired immune deficiency syndromes (1999) 20101001

• Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.

  Pharmacotherapy 20101001

• A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.

  Electrophoresis 20101001

• Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.

  AIDS (London, England) 20100924

• Use of abacavir in 30 HIV-infected children from Durban, South Africa: report from a pilot study.

  The Pediatric infectious disease journal 20100901

• Development and validation of a selective and rapid LC-MS-MS method for the quantification of abacavir in human plasma.

  Journal of chromatographic science 20100901

• Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

  AIDS (London, England) 20100824

• First report of abacavir associated with hypoglycemia.

  AIDS (London, England) 20100824

• Abacavir and cardiovascular risk: reviewing the evidence.

  Current HIV/AIDS reports 20100801

• Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

  The Journal of antimicrobial chemotherapy 20100801

• [Pharmacogenetics].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801

• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  Archives of internal medicine 20100726

• Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

  AIDS (London, England) 20100717

• Pharmacogenetics of drug hypersensitivity.

  Pharmacogenomics 20100701

• Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir.

  Cardiovascular toxicology 20100601

• Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.

  AIDS (London, England) 20100601

• Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.

  AIDS patient care and STDs 20100601

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20100601

• Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.

  AIDS (London, England) 20100515

• Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.

  Medical mycology 20100501

• Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

  HIV medicine 20100501

• Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

  HIV medicine 20100501

• [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].

  MMW Fortschritte der Medizin 20100429

• Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.

  Pharmacogenomics 20100401

• Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management.

  AIDS (London, England) 20100327

• Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

  AIDS (London, England) 20100313

• Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.

  HIV medicine 20100301

• Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.

  HIV medicine 20100301

• A model-based approach to dose selection in early pediatric development.

  Clinical pharmacology and therapeutics 20100301

• [Durability and tolerability of long-term nevirapine-based HAART].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20100301

• Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

  HIV medicine 20100201

• Abacavir and cardiovascular risk.

  Current opinion in infectious diseases 20100201

• HIV treatment information.

  Project Inform perspective 20100201

• Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

  AIDS (London, England) 20100128

• Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

  Archives of internal medicine 20100111

• Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

  Lancet (London, England) 20100109

• Pharmacogenetics of antiretrovirals.

  Antiviral research 20100101

• Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

  Tissue antigens 20100101

• Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.

  The Journal of infectious diseases 20100101

• Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.

  Antiviral therapy 20100101

• The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.

  Antiviral therapy 20100101

• Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

  Antiviral therapy 20100101

• Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV clinical trials 20100101

• Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany.

  European journal of medical research 20100101

• Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

  PharmacoEconomics 20100101

• Abacavir and CVD--more data but no consensus. Studies this year were evenly split, leaving patients and clinicians with few answers.

  Journal watch. AIDS clinical care 20100101

• Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.

  HIV clinical trials 20100101

• Anti-retroviral therapy-induced status epilepticus in 'pseudo-HIV serodeconversion'.

  General hospital psychiatry 20100101

• Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

  Antiviral therapy 20100101

• The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines.

  PloS one 20100101

• HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20100101

• A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

  HIV clinical trials 20100101

• Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine.

  Journal of pharmaceutical and biomedical analysis 20091205

• Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus.

  Clinical and experimental dermatology 20091201

• Abacavir and lamivudine combination.

  Expert opinion on drug metabolism & toxicology 20091201

• Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.

  AIDS research and human retroviruses 20091201

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.

  AIDS patient care and STDs 20091101

• Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.

  HIV medicine 20091101

• Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

  Infection 20091001

• Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.

  Journal watch. AIDS clinical care 20091001

• Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.

  AIDS (London, England) 20090924

• B-mode ultrasound study of carotid plaques in HIV-positive patients to detect the presence of inflammatory endothelial lesions.

  Current HIV research 20090901

• Virological response to initial antiretroviral regimens containing abacavir or tenofovir.

  The Journal of infectious diseases 20090901

• Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.

  Arteriosclerosis, thrombosis, and vascular biology 20090901

• [Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20090901

• FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.

  AIDS alert 20090901

• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

  AIDS (London, England) 20090731

• The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.

  International journal of cancer 20090701

• A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

  HIV medicine 20090701

• The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

  AIDS research and human retroviruses 20090701

• Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20090601

• HLA and drug-induced toxicity.

  Current opinion in molecular therapeutics 20090601

• Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

  The Journal of antimicrobial chemotherapy 20090501

• Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?

  Current HIV research 20090501

• [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].

  MMW Fortschritte der Medizin 20090430

• Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20090415

• Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.

  Journal of chromatography. A 20090410

• Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.

  Clinical pharmacology and therapeutics 20090401

• Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.

  The Journal of pharmacology and experimental therapeutics 20090401

• Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative.

  International journal of STD & AIDS 20090401

• Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

  AIDS research and human retroviruses 20090401

• CROI 2009: a few key presentations on antiretroviral therapy.

  The AIDS reader 20090401

• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  The AIDS reader 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. Continued concern about abacavir and cardiovascular risk.

  Journal watch. AIDS clinical care 20090401

• Aid agencies condemn drug confiscation.

  BMJ (Clinical research ed.) 20090311

• Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20090301

• Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.

  The pharmacogenomics journal 20090201

• Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090201

• Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.

  Pharmacogenomics 20090201

• FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.

  AIDS alert 20090201

• FDA notifications. Abacavir approved for pediatric patients.

  AIDS alert 20090201

• [Atazanavir-induced nephrolithiasis].

  Enfermedades infecciosas y microbiologia clinica 20090201

• The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101

• Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

  The Journal of infectious diseases 20090101

• Top stories of 2008. Abacavir turmoil.

  AIDS clinical care 20090101

• Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.

  AIDS clinical care 20090101

• Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?

  Antiviral therapy 20090101

• Successful translation of pharmacogenetics into the clinic: the abacavir example.

  Molecular diagnosis & therapy 20090101

• Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).

  HIV clinical trials 20090101

• Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF.

  HIV clinical trials 20090101

• HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.

  Critical reviews in clinical laboratory sciences 20090101

• [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

  The pharmacogenomics journal 20081201

• Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

  The Journal of antimicrobial chemotherapy 20081201

• Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081201

• Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

  Genetics in medicine : official journal of the American College of Medical Genetics 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.

  AIDS clinical care 20081201

• Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.

  AIDS (London, England) 20081130

• Abacavir-induced hepatotoxicity: a report of two cases.

  AIDS (London, England) 20081130

• Generic lamivudine and abacavir approved.

  AIDS patient care and STDs 20081101

• FDA notifications. Abacavir tablet approved for pediatric patients.

  AIDS alert 20081101

• Abacavir-induced febrile agranulocytosis and anaemia.

  AIDS (London, England) 20081018

• Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

  HIV medicine 20081001

• Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.

  AIDS patient care and STDs 20081001

• Comment: Abacavir hypersensitivity reaction: an update.

  The Annals of pharmacotherapy 20081001

• The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

  AIDS (London, England) 20081001

• Current trends in screening across ethnicities for hypersensitivity to abacavir.

  Pharmacogenomics 20081001

• FDA notifications. Generic abacavir and lamivudine combo approved.

  AIDS alert 20081001

• The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir.

  The Journal of infectious diseases 20080915

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

  AIDS (London, England) 20080912

• The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research.

  American journal of human genetics 20080912

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Cariogenic and erosive potential of the medication used by HIV-infected children: pH and sugar concentration.

  Community dental health 20080901

• FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed.

  AIDS alert 20080901

• Abacavir controversy continues to brew.

  Project Inform perspective 20080901

• First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

  AIDS (London, England) 20080820

• Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.

  HIV medicine 20080801

• The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

  Journal of acquired immune deficiency syndromes (1999) 20080801

• Labeling changes for abacavir.

  AIDS patient care and STDs 20080801

• CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.

  The AIDS reader 20080801

• An unusual abacavir reaction.

  AIDS (London, England) 20080731

• Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative.

  AIDS (London, England) 20080731

• Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.

  The Journal of infection 20080701

• Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.

  AIDS research and human retroviruses 20080701

• Abacavir hypersensitivity.

  The New England journal of medicine 20080605

• Abacavir hypersensitivity.

  The New England journal of medicine 20080605

• Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

  Immunity 20080601

• Pharmacogenomics of antiretrovirals.

  Recent patents on anti-infective drug discovery 20080601

• A review of drug patch testing and implications for HIV clinicians.

  AIDS (London, England) 20080531

• Abacavir and warfarin modulate allosterically kinetics of NO dissociation from ferrous nitrosylated human serum heme-albumin.

  Biochemical and biophysical research communications 20080502

• Cardiac tamponade: an unusual complication of simultaneous treatment of tuberculosis and HIV.

  Southern medical journal 20080501

• Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• FDA reviewing safety of Ziagen and Videx.

  The AIDS reader 20080501

• [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].

  Lakartidningen 20080501

• FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.

  AIDS alert 20080501

• [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].

  Enfermedades infecciosas y microbiologia clinica 20080501

• [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

  Enfermedades infecciosas y microbiologia clinica 20080501

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  Lancet (London, England) 20080426

• Abacavir and the potential risk of myocardial infarction.

  Lancet (London, England) 20080426

• Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.

  AIDS patient care and STDs 20080401

• Heart attack risk with abacavir and didanosine.

  AIDS patient care and STDs 20080401

• High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080401

• Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk?

  AIDS clinical care 20080401

• Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.

  AIDS clinical care 20080401

• Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301

• Abacavir hypersensitivity reaction: an update.

  The Annals of pharmacotherapy 20080301

• Abacavir and didanosine increase the risk of heart attack.

  AIDS patient care and STDs 20080301

• Anti-HIV agents. Controversial findings on abacavir and heart attacks.

  TreatmentUpdate 20080301

• HLA-B*5701 screening for hypersensitivity to abacavir.

  The New England journal of medicine 20080207

• Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.

  The New England journal of medicine 20080207

• Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.

  HIV medicine 20080201

• Pharmacogenetic information derived from analysis of HLA alleles.

  Pharmacogenomics 20080201

• PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.

  Pharmaceutical statistics 20080101

• Electrochemical determination of HIV drug Abacavir based on its reduction.

  Analytical chemistry 20080101

• Treatment options for lipodystrophy in HIV-positive patients.

  Expert opinion on pharmacotherapy 20080101

• Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response.

  HIV medicine 20080101

• Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

  HIV clinical trials 20080101

• Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).

  Tropical medicine & international health : TM & IH 20080101

• New formulations approved for children.

  AIDS patient care and STDs 20080101

• A review of the pharmacokinetics of abacavir.

  Clinical pharmacokinetics 20080101

• Cytokine profiling in abacavir hypersensitivity patients.

  Antiviral therapy 20080101

• Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.

  HIV clinical trials 20080101

• Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

  Antiviral therapy 20080101

• Incidence of abacavir hypersensitivity reactions in euroSIDA.

  Antiviral therapy 20080101

• Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

  Antiviral therapy 20080101

• XVII International AIDS Conference--Mexico City, August 3-8, 2008. Can Ziagen hurt your heart? Research presented at the International AIDS Conference weighs in on the controversy.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.

  Antiviral therapy 20080101

• Dosage adjustments in hepatic dysfunction.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215

• Screening for abacavir hypersensitivity.

  AIDS alert 20071201

• Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

  AIDS (London, England) 20071130

• P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.

  Drug metabolism and disposition: the biological fate of chemicals 20071101

• Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071101

• Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

  AIDS research and human retroviruses 20071101

• Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.

  AIDS (London, England) 20071018

• Large lymphadenopathies complicating the abacavir hypersensitivity reaction.

  AIDS (London, England) 20071018

• [Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients].

  Medecine et maladies infectieuses 20071001

• Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction.

  AIDS (London, England) 20071001

• HLA-B*5701 clinical testing: early experience in the United States.

  Pharmacogenetics and genomics 20071001

• Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.

  The AIDS reader 20071001

• Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.

  AIDS clinical care 20071001

• Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.

  AIDS (London, England) 20070912

• A comparison of three initial antiretroviral AIDS regimens.

  The New England journal of medicine 20070906

• Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.

  Antiviral research 20070901

• Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.

  The Journal of antimicrobial chemotherapy 20070901

• Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?

  AIDS (London, England) 20070820

• Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Human leukocyte antigens and drug hypersensitivity.

  Current opinion in allergy and clinical immunology 20070801

• Drug hypersensitivity in HIV.

  Current opinion in allergy and clinical immunology 20070801

• Hair loss induced by lopinavir-ritonavir.

  Pharmacotherapy 20070801

• Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.

  Tissue antigens 20070701

• Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

  AIDS (London, England) 20070619

• Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.

  Sexually transmitted infections 20070601

• A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• 'Personalized medicine: elusive dream or imminent reality?': A commentary.

  Clinical pharmacology and therapeutics 20070601

• Abacavir sulfate and mania in HIV.

  The American journal of psychiatry 20070601

• HPV oral infection. Case report of an HIV-positive Nigerian sex worker.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20070601

• FDA notifications. FDA grants approval for generic didanosine for oral solution.

  AIDS alert 20070601

• Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1.

  AIDS (London, England) 20070511

• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

  AIDS (London, England) 20070511

• Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Advances in HIV therapeutics: the 14th CROI.

  The AIDS reader 20070501

• Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).

  Journal of acquired immune deficiency syndromes (1999) 20070415

• Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

  The Journal of infectious diseases 20070415

• HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.

  The Journal of antimicrobial chemotherapy 20070401

• Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.

  AIDS patient care and STDs 20070401

• Identification of abacavir hypersensitivity reaction in health care claims data.

  Pharmacoepidemiology and drug safety 20070301

• Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

  Pediatrics 20070301

• Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.

  Expert opinion on pharmacotherapy 20070301

• Abacavir modulates peroxynitrite-mediated oxidation of ferrous nitrosylated human serum heme-albumin.

  Biochemical and biophysical research communications 20070209

• Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

  Journal of acquired immune deficiency syndromes (1999) 20070201

• Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.

  AIDS (London, England) 20070130

• Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070101

• Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.

  AIDS patient care and STDs 20070101

• Development and validation of a reverse-phase liquid chromatographic method for assay and related substances of abacavir sulfate.

  Journal of separation science 20070101

• Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations.

  Environmental and molecular mutagenesis 20070101

• The NEFA study: results at three years.

  AIDS reviews 20070101

• Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.

  HIV clinical trials 20070101

• Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.

  Antiviral therapy 20070101

• Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

  Antiviral therapy 20070101

• Complications and side effects. Abacavir hypersensitivity testing results--Montreal.

  TreatmentUpdate 20070101

• External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

  Antiviral therapy 20070101

• Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20070101

• A new and short convergent synthetic strategy to carbocyclic nucleosides.

  Nucleosides, nucleotides & nucleic acids 20070101

• [Pilot study of antiretroviral therapy in Djibouti].

  Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20070101

• In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

  Antimicrobial agents and chemotherapy 20061201

• Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.

  The Pediatric infectious disease journal 20061201

• Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review.

  Medical science monitor : international medical journal of experimental and clinical research 20061201

• Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.

  Expert opinion on pharmacotherapy 20061201

• FDA approves generic abacavir sulfate tablets.

  AIDS alert 20061201

• Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.

  AIDS clinical care 20061101

• A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

  AIDS (London, England) 20061024

• Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

  AIDS (London, England) 20061024

• The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.

  AIDS research and human retroviruses 20061001

• Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.

  Optometry (St. Louis, Mo.) 20060901

• Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.

  AIDS patient care and STDs 20060901

• Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

  JAMA 20060816

• The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

  Lancet (London, England) 20060805

• Human genetic variability and HIV treatment response.

  Current HIV/AIDS reports 20060701

• A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

  The Journal of infectious diseases 20060701

• Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701

• Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701

• Synthesis of carbovir and abacavir from a carbocyclic precursor.

  Current protocols in nucleic acid chemistry 20060701

• Investigating new antiretroviral combinations.

  The Journal of infectious diseases 20060615

• Abacavir hypersensitivity reaction in primary HIV infection.

  AIDS (London, England) 20060612

• Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060601

• Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

  The Pediatric infectious disease journal 20060601

• The clinical implications of antiretroviral pharmacogenomics.

  Pharmacogenomics 20060601

• Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions.

  International journal of clinical pharmacology and therapeutics 20060601

• [Antiretroviral treatment associated life-threatening adverse events].

  Medicina clinica 20060520

• A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.

  Pharmacogenetics and genomics 20060501

• Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?

  International journal of clinical practice 20060501

• Abacavir prodrugs: microwave-assisted synthesis and their evaluation of anti-HIV activities.

  Bioorganic & medicinal chemistry letters 20060415

• Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

  Journal of acquired immune deficiency syndromes (1999) 20060415

• Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.

  The Pediatric infectious disease journal 20060401

• Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

  The AAPS journal 20060301

• Impact of pregnancy on abacavir pharmacokinetics.

  AIDS (London, England) 20060227

• Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.

  Journal of acquired immune deficiency syndromes (1999) 20060201

• Acute respiratory manifestations of the abacavir hypersensitivity reaction.

  AIDS (London, England) 20060109

• Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

  Pharmacogenomics 20060101

• An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.

  Antiviral therapy 20060101

• Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.

  Drug safety 20060101

• Genetic testing may avoid abacavir hypersensitivity reaction.

  AIDS treatment news 20060101

• Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.

  Journal of postgraduate medicine 20060101

• An immunological comparison of third companion in advanced drug-naive HIV-infected patients.

  HIV clinical trials 20060101

• Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

  HIV clinical trials 20060101

• Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.

  HIV clinical trials 20060101

• [Development and validation of laboratory methods for antiretroviral quantitation using HPLC].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.

  Antiviral therapy 20060101

• Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.

  The Journal of infectious diseases 20051201

• Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

  The Journal of infectious diseases 20051201

• Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

  Journal of acquired immune deficiency syndromes (1999) 20051201

• Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.

  Expert review of anti-infective therapy 20051201

• Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.

  AIDS (London, England) 20051104

• Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

  HIV medicine 20051101

• Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

  AIDS (London, England) 20050902

• Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

  Journal of acquired immune deficiency syndromes (1999) 20050815

• Fatal lactic acidosis associated with tenofovir and abacavir.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20050701

• Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Abacavir dosing with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615

• Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.

  AIDS (London, England) 20050610

• Clinical and immunogenetic correlates of abacavir hypersensitivity.

  AIDS (London, England) 20050610

• [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection].

  Presse medicale (Paris, France : 1983) 20050604

• Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.

  Mutation research 20050603

• HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.

  Tissue antigens 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.

  AIDS (London, England) 20050520

• Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.

  Journal of medicinal chemistry 20050519

• Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.

  The Journal of allergy and clinical immunology 20050501

• The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.

  HIV medicine 20050501

• Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

  Journal of acquired immune deficiency syndromes (1999) 20050415

• Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

  Journal of acquired immune deficiency syndromes (1999) 20050401

• [Toxic epidermal necrolysis associated with abacavir].

  Enfermedades infecciosas y microbiologia clinica 20050401

• Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

  AIDS (London, England) 20050325

• Abacavir pharmacokinetics in hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050315

• Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.

  Journal of clinical pharmacology 20050301

• Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050301

• Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

  AIDS patient care and STDs 20050301

• Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.

  HIV medicine 20050301

• Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225

• A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

  The Journal of antimicrobial chemotherapy 20050201

• Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

  Journal of acquired immune deficiency syndromes (1999) 20050201

• Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

  British journal of clinical pharmacology 20050201

• The impact of abacavir on lipids and lipodystrophy.

  The AIDS reader 20050201

• GlaxoSmithKline receives European approval for Kivexa.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20050201

• Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.

  AIDS (London, England) 20050103

• Lipoatrophy and mitochondrial DNA assays: see all, know all?

  AIDS (London, England) 20050103

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.

  Drugs 20050101

• Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

  BMC infectious diseases 20050101

• Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.

  AIDS patient care and STDs 20050101

• Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.

  AIDS clinical care 20050101

• Quadruple-drug induction HAART in advanced HIV infection.

  HIV clinical trials 20050101

• Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

  BMC infectious diseases 20050101

• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

  Antiviral therapy 20050101

• In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.

  Antiviral therapy 20050101

• Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.

  Clinical pharmacokinetics 20050101

• Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

  Antiviral therapy 20050101

• Once-daily abacavir in place of twice-daily administration.

  The Annals of pharmacotherapy 20050101

• [An analisys fo causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050101

• Will pharmacogenomic discoveries improve HIV therapeutics?

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.

  Current pharmaceutical design 20050101

• Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.

  AIDS treatment news 20050101

• Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.

  HIV clinical trials 20050101

• Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.

  HIV clinical trials 20050101

• Anti-HIV agents. Abacavir once or twice daily.

  TreatmentUpdate 20050101

• Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?

  Neurology 20041228

• More on abacavir-induced neuropsychiatric reactions.

  AIDS (London, England) 20041203

• Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function.

  Biomedical chromatography : BMC 20041201

• Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir.

  The Annals of pharmacotherapy 20041201

• Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study.

  AIDS research and human retroviruses 20041201

• No rechallenge for abacavir.

  AIDS patient care and STDs 20041201

• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.

  AIDS (London, England) 20041105

• Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.

  AIDS (London, England) 20041105

• Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir.

  Biochemical pharmacology 20041101

• [Risk factors for Abacavir-induced hypersensibility syndrome in the 'real world'].

  Pathologie-biologie 20041101

• Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

  HIV medicine 20041101

• Tenofovir use in a patient with a severe renal impairment.

  HIV medicine 20041101

• HLA-B*5701 and abacavir hypersensitivity.

  Pharmacogenetics 20041101

• Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.

  Journal of virological methods 20041001

• Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041001

• Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

  Antiviral therapy 20041001

• Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.

  AIDS (London, England) 20040903

• Sweet's syndrome following abacavir therapy.

  Journal of the American Academy of Dermatology 20040901

• Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.

  FEBS letters 20040827

• Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

  AIDS (London, England) 20040820

• Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

  The Journal of infectious diseases 20040815

• Triple-nucleoside regimens versus efavirenz.

  The New England journal of medicine 20040812

• Triple-nucleoside regimens versus efavirenz.

  The New England journal of medicine 20040812

• Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• The pharmacogenetics of antiretroviral therapy: a review of studies to date.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040701

• Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.

  The Journal of clinical endocrinology and metabolism 20040701

• Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

  Current medical research and opinion 20040701

• Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.

  Current medical research and opinion 20040701

• In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.

  Antiviral research 20040601

• Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• Bringing genomics to the bedside: a cost-effective pharmacogenomic test?

  Pharmacogenetics 20040601

• Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

  Pharmacogenetics 20040601

• Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

  AIDS (London, England) 20040430

• Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

  The New England journal of medicine 20040429

• [Valuable combination partner. Great benefit for therapy naive patients].

  MMW Fortschritte der Medizin 20040426

• Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

  AIDS (London, England) 20040409

• Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors.

  Journal of neurovirology 20040401

• Abacavir hypersensitivity reaction predicted by genetic test.

  AIDS treatment news 20040326

• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

  Proceedings of the National Academy of Sciences of the United States of America 20040323

• [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].

  Praxis 20040303

• Comment: Reasons for early abacavir discontinuation in HIV-infected patients.

  The Annals of pharmacotherapy 20040301

• Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

  Pharmacogenomics 20040301

• Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.

  AIDS (London, England) 20040220

• Managing HIV lipoatrophy.

  Lancet (London, England) 20040207

• Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.

  Antiviral research 20040201

• Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20040201

• Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.

  AIDS (London, England) 20040123

• Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040115

• Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

  Antimicrobial agents and chemotherapy 20040101

• The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Determination of Abacavir in maternal plasma, amniotic fluid, fetal and placental tissues by a polarity switching liquid chromatography/tandem mass spectrometry method.

  Rapid communications in mass spectrometry : RCM 20040101

• Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs?

  Journal of neurovirology 20040101

• The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection.

  Scandinavian journal of infectious diseases 20040101

• Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.

  HIV clinical trials 20040101

• Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.

  AIDS (London, England) 20040101

• EU issues warning about HAART regimen.

  AIDS patient care and STDs 20040101

• Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients.

  HIV clinical trials 20040101

• Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.

  The Annals of pharmacotherapy 20040101

• Pharmacogenetics to predict drug-related adverse events.

  Toxicologic pathology 20040101

• K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.

  MedGenMed : Medscape general medicine 20040101

• Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

  Psychosomatics 20040101

• [Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101

• Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.

  HIV clinical trials 20040101

• Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.

  Lancet (London, England) 20031213

• TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

  AIDS (London, England) 20031205

• [Delayed drug sensitivity].

  Revista clinica espanola 20031201

• A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

  Antiviral therapy 20031201

• The continuing evolution of HIV therapy.

  The AIDS reader 20031201

• Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.

  AIDS (London, England) 20031121

• Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.

  AIDS (London, England) 20031121

• Unusual clinical presentation of hypersensitivity reaction to abacavir.

  AIDS (London, England) 20031107

• Triple combinations regimens for HIV.

  The Lancet. Infectious diseases 20031101

• Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.

  Pharmacotherapy 20031101

• Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.

  The AIDS reader 20031101

• Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.

  AIDS clinical care 20031101

• Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.

  AIDS clinical care 20031101

• Early nonresponse for tenofovir regimen.

  AIDS patient care and STDs 20031101

• [Hypersensitive reaction to abacavir or syphilitic hepatitis?].

  Presse medicale (Paris, France : 1983) 20031011

• Reasons for early abacavir discontinuation in HIV-infected patients.

  The Annals of pharmacotherapy 20031001

• Epidemiological risk factors for hypersensitivity reactions to abacavir.

  HIV medicine 20031001

• Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20031001

• Warning issued on non-response rates.

  AIDS patient care and STDs 20031001

• Anti-HIV agents. Trying times for tenofovir and abacavir.

  TreatmentUpdate 20031001

• Anti-HIV agents. Abacavir--as good as AZT?

  TreatmentUpdate 20031001

• Anti-HIV agents. Abacavir only once-daily.

  TreatmentUpdate 20031001

• Anti-HIV agents. Who gets abacavir allergies?

  TreatmentUpdate 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

  The New England journal of medicine 20030911

• [Antiretroviral-induced toxiderma in HIV-infected patients].

  Presse medicale (Paris, France : 1983) 20030906

• Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901

• GlaxoSmithKline halts AIDS study.

  The Lancet. Infectious diseases 20030901

• Perspectives on HAART: switch maintenance therapy.

  International journal of STD & AIDS 20030901

• Capillary electrophoresis-ion trap mass spectrometry analysis of Ziagen and its phosphorylated metabolites.

  Electrophoresis 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.

  AIDS clinical care 20030901

• Clinically relevant interpretation of genotype for resistance to abacavir.

  AIDS (London, England) 20030815

• Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• [Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].

  Revista clinica espanola 20030801

• Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

  The Journal of infectious diseases 20030801

• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

  Antiviral therapy 20030801

• Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.

  Antiviral therapy 20030801

• Early intensification with abacavir in subjects at high risk for incomplete viral suppression.

  Antiviral therapy 20030801

• Failure of combination abacavir + tenofovir + lamivudine (3TC).

  AIDS treatment news 20030725

• Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.

  International journal of STD & AIDS 20030701

• AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• Abandon Trizivir when it's working well? A rebuttal.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.

  Antimicrobial agents and chemotherapy 20030601

• Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• Cutaneous manifestations of antiviral therapy.

  Journal of the American Academy of Dermatology 20030601

• A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.

  Journal of acquired immune deficiency syndromes (1999) 20030501

• Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030501

• Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

  Journal of HIV therapy 20030501

• Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system.

  Journal of HIV therapy 20030501

• Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.

  AIDS (London, England) 20030411

• Abacavir arm stopped in clinical trial.

  AIDS treatment news 20030404

• Antiretroviral therapy-induced psychosis: case report and brief review of the literature.

  HIV medicine 20030401

• HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

  Antiviral therapy 20030401

• Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.

  Antiviral therapy 20030401

• Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

  Antiviral therapy 20030401

• K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

  Antiviral therapy 20030401

• Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20030301

• Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.

  AIDS (London, England) 20030214

• Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

  Antiviral therapy 20030201

• Thymidine analogue-sparing highly active antiretroviral therapy (HAART).

  Journal of HIV therapy 20030201

• Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

  The Journal of infectious diseases 20030101

• Lamivudine/zidovudine/abacavir: triple combination tablet.

  Drugs 20030101

• Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.

  HIV clinical trials 20030101

• Clinical vignette in antiretroviral therapy: rash illness.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20030101

• Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.

  Positively aware : the monthly journal of the Test Positive Aware Network 20030101

• Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection.

  Journal of intensive care medicine 20030101

• Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.

  AIDS (London, England) 20021206

• Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

  Antiviral therapy 20021201

• Chronic cough induced by abacavir apart from a context of hypersensitivity.

  Allergie et immunologie 20021201

• The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.

  Chemico-biological interactions 20021110

• Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.

  AIDS (London, England) 20021108

• The importance of being modest--reflections on the pharmacogenetics of abacavir.

  Pharmacogenomics 20021101

• Neuropsychiatric reaction induced by abacavir.

  The American journal of medicine 20021101

• Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

  The Journal of biological chemistry 20021025

• The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

  AIDS (London, England) 20021018

• Stevens-Johnson syndrome associated with abacavir therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021001

• Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• The abacavir hypersensitivity reaction: a review.

  Clinical therapeutics 20021001

• The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction.

  AIDS (London, England) 20020816

• FDA notifications. Product tampering labels Ziagen as Combivir.

  AIDS alert 20020801

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

  JAMA 20020710

• Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

  AIDS (London, England) 20020705

• Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.

  Antiviral research 20020701

• Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.

  The Journal of pediatrics 20020701

• Genome-based pharmacogenetics and the pharmaceutical industry.

  Nature reviews. Drug discovery 20020701

• Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug.

  AIDS (London, England) 20020614

• Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

  AIDS (London, England) 20020524

• Therapeutic vaccination in primary HIV infection, the Quest trial.

  Vaccine 20020506

• Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.

  AIDS (London, England) 20020503

• Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.

  AIDS (London, England) 20020503

• A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

  The Journal of infectious diseases 20020501

• Abacavir hypersensitivity reaction.

  AIDS patient care and STDs 20020501

• HLA B57 and abacavir hypersensitivity.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20020501

• Abacavir hypersensitivity reaction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415

• Scientists find some genes a bad omen for anti-HIV drug.

  JAMA 20020403

• Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

  Antiviral research 20020401

• Risk factor analysis of hypersensitivity reactions to abacavir.

  Clinical therapeutics 20020401

• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  Lancet (London, England) 20020330

• Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.

  AIDS (London, England) 20020329

• Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.

  AIDS (London, England) 20020308

• Individualising HIV treatment--pharmacogenetics and immunogenetics.

  Lancet (London, England) 20020302

• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  Lancet (London, England) 20020302

• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.

  Lancet (London, England) 20020302

• Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

  Antiviral therapy 20020301

• Switching to abacavir to reduce fat wasting.

  TreatmentUpdate 20020301

• Using abacavir to avoid lipid problems.

  TreatmentUpdate 20020301

• Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215

• Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215

• HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.

  AIDS (London, England) 20020215

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

  AIDS research and human retroviruses 20020120

• Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.

  Antiviral research 20020101

• Kawasaki-like syndrome: abacavir hypersensitivity?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020101

• Antiretroviral rounds. A very discordant response.

  AIDS clinical care 20020101

• Vertigo and abacavir.

  AIDS patient care and STDs 20020101

• Easier abacavir regimen has promising results.

  AIDS alert 20020101

• 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.

  Positive living (Los Angeles, Calif.) 20020101

• Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.

  HIV clinical trials 20020101

• Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.

  AIDS (London, England) 20011207

• Agranulocytosis and fever seven weeks after starting abacavir.

  AIDS (London, England) 20011207

• Understanding drug hypersensitivity: what to look for when prescribing abacavir.

  The AIDS reader 20011201

• Editorial comment: the challenge of prescribing abacavir.

  The AIDS reader 20011201

• Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

  Proceedings of the National Academy of Sciences of the United States of America 20011120

• Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.

  AIDS (London, England) 20011109

• The role of NNRTIs in antiretroviral combination therapy: an introduction.

  International journal of STD & AIDS 20011101

• Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.

  European journal of medical research 20011029

• High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid.

  Journal of chromatography. B, Biomedical sciences and applications 20011025

• Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015

• Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

  Therapeutic drug monitoring 20011001

• Hypersensitivity related to abacavir in two members of a family.

  The Annals of pharmacotherapy 20011001

• Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

  Clinical therapeutics 20011001

• HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

  AIDS (London, England) 20010928

• Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.

  The Journal of infectious diseases 20010915

• [Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].

  MMW Fortschritte der Medizin 20010906

• Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid.

  The Journal of pharmacology and experimental therapeutics 20010901

• Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.

  Nephron 20010901

• Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.

  Antiviral chemistry & chemotherapy 20010901

• Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

  AIDS (London, England) 20010817

• The abacavir hypersensitivity reaction and interruptions in therapy.

  AIDS (London, England) 20010706

• Resistance and cross-resistance to abacavir.

  HIV medicine 20010701

• Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.

  Antiviral therapy 20010601

• Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.

  Antiviral therapy 20010601

• A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.

  Antiviral therapy 20010601

• Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010501

• Choosing which nuke to use first.

  The AIDS reader 20010501

• Drifting agenda for federal treatment research.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20010501

• Resistant to everything.

  AIDS clinical care 20010501

• Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Biomedical sciences and applications 20010425

• HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

  AIDS (London, England) 20010413

• [Observational study with abacavir. Decreased viral load and quality of life improves].

  MMW Fortschritte der Medizin 20010402

• [Determining resistance in HIV therapy. Careful interpretation only].

  MMW Fortschritte der Medizin 20010402

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.

  Pharmacotherapy 20010401

• Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• A near-fatal hypersensitivity reaction to abacavir: case report and literature review.

  The AIDS reader 20010401

• Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

  JAMA 20010307

• Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.

  The Journal of infectious diseases 20010301

• International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

  Journal of acquired immune deficiency syndromes (1999) 20010301

• Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.

  Journal of clinical pharmacology 20010301

• Phase III trials for new PI.

  AIDS patient care and STDs 20010301

• Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

  The Journal of infectious diseases 20010215

• Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

  AIDS (London, England) 20010126

• Abacavir and diabetes.

  The New England journal of medicine 20010111

• Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.

  Journal of chromatography. B, Biomedical sciences and applications 20010105

• A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

  Pediatrics 20010101

• Trizivir on the market.

  Trends in microbiology 20010101

• Triple-drug tablet approved for HIV infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101

• Triple nuke therapy--results after one year.

  TreatmentUpdate 20010101

• Abacavir sulfate, lamivudine, and zidovudine (Trizivir).

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.

  HIV medicine 20010101

• Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

  AIDS research and human retroviruses 20000410

• Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.

  Journal of acquired immune deficiency syndromes (1999) 19990815

• Four new antiretroviral medications will soon offer more options to HIV patients.

  Faculty notes (New Orleans, La.) 19980101

• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

  Antimicrobial agents and chemotherapy 19970501

• Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.

  Antimicrobial agents and chemotherapy 19970501

• Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.

  Antimicrobial agents and chemotherapy 19970501